Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care

E. Rassy; B. Pistilli

doi:10.1016/j.annonc.2021.08.1750

Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care

E. Rassy, B. Pistilli

Résultats de recherche: Contribution à un journal › Editorial

langue originale	Anglais
Pages (de - à)	1206-1208
Nombre de pages	3
journal	Annals of Oncology
Volume	32
Numéro de publication	10
Les DOIs	https://doi.org/10.1016/j.annonc.2021.08.1750
état	Publié - 1 oct. 2021

Accès au document

10.1016/j.annonc.2021.08.1750

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{40142988c58946b594400870d96be5d4,

title = "Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care",

author = "E. Rassy and B. Pistilli",

note = "Funding Information: None declared. BP: Consulting/Advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; Personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; Research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca. ER has declared no conflicts of interest.",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.annonc.2021.08.1750",

language = "English",

volume = "32",

pages = "1206--1208",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "10",

}

TY - JOUR

T1 - Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care

AU - Rassy, E.

AU - Pistilli, B.

N1 - Funding Information: None declared. BP: Consulting/Advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; Personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; Research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca. ER has declared no conflicts of interest.

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85114510661&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.08.1750

DO - 10.1016/j.annonc.2021.08.1750

M3 - Editorial

C2 - 34403778

AN - SCOPUS:85114510661

SN - 0923-7534

VL - 32

SP - 1206

EP - 1208

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -